MaxCyte, Inc. Disclosure of Remuneration for Non-Audit Services (9790C)
October 22 2020 - 1:22PM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 9790C
MaxCyte, Inc.
22 October 2020
Disclosure of Remuneration for Non-Audit Services
Gaithersburg, Maryland - 22 October 2020: MaxCyte, Inc. (LSE:
MXCT, MXCL), a global cell-based therapies and life sciences
company, today announces an update to its previous disclosure of
remuneration for audit-related services.
The Company previously disclosed on 14 October 2020 that the
remuneration of the Company's auditors, Cohn Rezhnick LLC, for
services relating to the 2019 financial year, amounted to
approximately $137,000.
In order to further assist investors in considering the
resolutions proposed ahead of the Company AGM, MaxCyte advises that
these fees consisted of $119,000 for audit services and $18,000 for
tax services, with no further costs incurred for any other
services.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
###
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-com
Mary-Jane Elliott
Chris Welsh
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKKBBBOBDDDKB
(END) Dow Jones Newswires
October 22, 2020 13:22 ET (17:22 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2023 to Apr 2024